We represent Canada’s innovative pharmaceutical industry

We aim to form effective alliances, support policies, improve Canada’s regulatory environment, and widen access to innovative medicines and ensure the effective protection of intellectual property.

Read our most recent policy, position and submission papers:

<strong>February 21, 2018</strong><br>Submission: Regulations Amending the Food and Drug Regulations (Public Release of Clinical Information) February 21, 2018
Submission: Regulations Amending the Food and Drug Regulations (Public Release of Clinical Information)
<strong>February 2018</strong><br><em>Mémoire : Innover pour un « avantage Québec » au bénéfice des patients et de l’économie du Québec</em> (Available in French only) February 2018
Mémoire : Innover pour un « avantage Québec » au bénéfice des patients et de l’économie du Québec (Available in French only)
<strong>February 12, 2018</strong><br>Canada Gazette, Part I – Regulations Amending the Patented Medicines Regulations February 12, 2018
Canada Gazette, Part I – Regulations Amending the Patented Medicines Regulations
<strong>January 8, 2018</strong><br>Canada-U.S. Regulatory Cooperation Council Consultation January 8, 2018
Canada-U.S. Regulatory Cooperation Council Consultation
<strong>December 18, 2017</strong><br>Cost Recovery Renewal Initiative - Consultation on Health Canada's Fee Proposal for Drugs and Medical Devices December 18, 2017
Cost Recovery Renewal Initiative - Consultation on Health Canada's Fee Proposal for Drugs and Medical Devices
<strong>November 23, 2017</strong><br>Consultation on Health Sector Payment Transparency Act, Bill 160 November 23, 2017
Consultation on Health Sector Payment Transparency Act, Bill 160
<strong>November 23, 2017</strong><br>External Review of Pan-Canadian Health Organizations November 23, 2017
External Review of Pan-Canadian Health Organizations
<strong>October 27, 2017</strong><br>Consultation on possible changes to the Food and Drug Regulations October 27, 2017
Consultation on possible changes to the Food and Drug Regulations
<strong>September 15, 2017</strong><br>Stakeholder Feedback on CADTH’s Proposed Revisions to the Biosimilar Review Process September 15, 2017
Stakeholder Feedback on CADTH’s Proposed Revisions to the Biosimilar Review Process
<strong>September 15, 2017</strong><br>Revising CADTH Common Drug Review Recommendations in the CADTH Therapeudic Review Process September 15, 2017
Revising CADTH Common Drug Review Recommendations in the CADTH Therapeudic Review Process
<strong>July 28, 2017</strong><br>Comments on Draft CETA Patented Medicines (Notice of Compliance) and Certificate of Supplementary Protection Regulations July 28, 2017
Comments on Draft CETA Patented Medicines (Notice of Compliance) and Certificate of Supplementary Protection Regulations
<strong>July 18, 2017</strong><br>Consultation for the Renegotiation and Modernization of the North American Free Trade Agreement (NAFTA) July 18, 2017
Consultation for the Renegotiation and Modernization of the North American Free Trade Agreement (NAFTA)
<strong>July 17, 2017</strong><br>Consultation on Canada's New Intellectual Property Strategy July 17, 2017
Consultation on Canada's New Intellectual Property Strategy
<strong>June 28, 2017</strong><br>PMPRB: Consultation Document, Protecting Canadians from Excessive Drug Prices June 28, 2017
PMPRB: Consultation Document, Protecting Canadians from Excessive Drug Prices
<strong>April 14, 2017</strong><br>Joint Response to Questions posed by the Canadian Association of Provincial Cancer Agencies April 14, 2017
Joint Response to Questions posed by the Canadian Association of Provincial Cancer Agencies
<strong>October 24, 2016</strong><br>Submission to the Patented Medicine Prices Review Board October 24, 2016
Submission to the Patented Medicine Prices Review Board
<strong>February 6, 2015</strong><br>Position Paper: Government’s Role In Addressing Prescription Drug Abuse February 6, 2015
Position Paper: Government’s Role In Addressing Prescription Drug Abuse